• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Gilead Sciences Could Dip a Little in Reaction to Earnings

The charts are looking soft right now.
By BRUCE KAMICH
Jul 27, 2020 | 02:50 PM EDT
Stocks quotes in this article: GILD

Gilead Sciences (GILD) is due to report earnings Tuesday. Let's review the charts that are looking a little "soft" right now.  

 
In this daily bar chart of GILD, below, we can see that prices are trading below the declining 50-day moving average line. The lows of May and June are not far below the market and so is the rising 200-day moving average line. They are all likely targets if the bears get the upper hand.
 
The On-Balance-Volume (OBV) line shows some weakness in the back half of July, and the Moving Average Convergence Divergence (MACD) oscillator is poised to cross below the zero line for a possible sell signal.  
 
 
In this daily Point and Figure chart of GILD, below, we can see a potential downside price target of around $69. 
 
 
 
 
Bottom line strategy: Consider reducing your long exposure on GILD ahead of earnings. 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology | Healthcare | Pharmaceuticals | Earnings Preview

More from Investing

Remember, Overbought and Extended Aren't the Same as Bearish and Broken Down

Bob Byrne
Aug 18, 2022 8:30 AM EDT

There is not sufficient technical evidence to assert that Wednesday's decline in stocks was the beginning of a severe decline.

Sloppy Wednesday, Parsing Retail Sales, Dissecting Fed Minutes, Shiny Apple

Stephen Guilfoyle
Aug 18, 2022 7:36 AM EDT

Plus, we check out how the market is handicapping future rate hikes and the latest GDP guesstimate out of the Atlanta Fed (it's lower again).

Take Advantage of Market Irrationality With This Stock

Paul Price
Aug 18, 2022 7:00 AM EDT

ACCO brands is a hidden gem with a 4.38% yield that you can own at a crazy low valuation. Let me show you how to play it.

Corrective Action Is Developing and Is Putting Bulls to the Test

James "Rev Shark" DePorre
Aug 18, 2022 6:32 AM EDT

We soon will see how much bullish support there really is.

Suddenly, a Fear of Heights on Wall Street

Helene Meisler
Aug 18, 2022 6:00 AM EDT

Sentiment anecdotally shifted on Wednesday. Let's take a look.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login